Yayın: Association BRCA mutation status between BMN 673 (talazoparib), an oral PARP inhibitor, in triple-negative breast cancer
| dc.contributor.author | Eskiler, Gamze Güney | |
| dc.contributor.buuauthor | Çeçener, Gülşah | |
| dc.contributor.buuauthor | Egeli, Ünal | |
| dc.contributor.buuauthor | Tunca, Berrin | |
| dc.contributor.department | Tıp Fakültesi | |
| dc.contributor.department | Tıbbi Biyoloji Ana Bilim Dalı | |
| dc.contributor.orcid | 0000-0002-1619-6680 | |
| dc.contributor.orcid | 0000-0001-7904-883X | |
| dc.contributor.orcid | 0000-0002-3820-424X | |
| dc.contributor.researcherid | ABI-6078-2020 | |
| dc.contributor.researcherid | AAH-1420-2021 | |
| dc.date.accessioned | 2024-01-12T06:08:00Z | |
| dc.date.available | 2024-01-12T06:08:00Z | |
| dc.date.issued | 2018-09 | |
| dc.description | Bu çalışma, 14-15 Eylül, 2018 tarihlerinde Paris[Fransa]’da düzenlenen Conference on Molecular Analysis for Personalised Therapy (MAP) Kongresi‘nde bildiri olarak sunulmuştur. | |
| dc.identifier.citation | Eskiler, G. G. vd. (2018). ''Association BRCA mutation status between BMN 673 (talazoparib), an oral PARP inhibitor, in triple-negative breast cancer''. Annals of Oncology, 29(Supplement 6). | |
| dc.identifier.doi | 10.1093/annonc/mdy314.008 | |
| dc.identifier.eissn | 1569-8041 | |
| dc.identifier.issn | 0923-7534 | |
| dc.identifier.issue | Supplement 6 | |
| dc.identifier.uri | https://www.sciencedirect.com/science/article/pii/S0923753419323026 | |
| dc.identifier.uri | https://hdl.handle.net/11452/38977 | |
| dc.identifier.volume | 29 | |
| dc.identifier.wos | 000458248200063 | |
| dc.indexed.wos | SCIE | |
| dc.indexed.wos | CPCIS | |
| dc.language.iso | en | |
| dc.publisher | Elsevier | |
| dc.relation.bap | BUAP(T)-2015/1 | |
| dc.relation.collaboration | Yurt içi | |
| dc.relation.journal | Annals of Oncology | |
| dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi | |
| dc.rights | info:eu-repo/semantics/openAccess | |
| dc.subject | Oncology | |
| dc.subject.wos | Oncology | |
| dc.title | Association BRCA mutation status between BMN 673 (talazoparib), an oral PARP inhibitor, in triple-negative breast cancer | |
| dc.type | Article | |
| dc.wos.quartile | Q1 (Oncology) | |
| dspace.entity.type | Publication | |
| local.contributor.department | Tıp Fakültesi/Tıbbi Biyoloji Ana Bilim Dalı | |
| local.indexed.at | WOS |
